IP Library › Granted Patent US 10,183,076
Granted Patent B2
US 10,183,076 · App. 15/286,578 · Granted Jan 22, 2019

Topical compositions for treatment of irritation of mucous membranes

Inventor: Shabtay Dikstein (Jerusalem, IL)
Assignee: RESDEVCO RESEARCH AND DEVELOPMENT CO. L
A61K47/10A61K8/00A61K9/0014A61K9/0034A61K9/0043A61K9/0048A61K9/06A61K47/14A61K47/183A61K47/186A61K47/26A61K47/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,183,076
App. No.
15/286,578
Granted
Jan 22, 2019
Kind
B2
Abstract

A topical pharmaceutical or cosmetic composition for treatment of irritation of mucous cells such as mucosal cells of the eye, nose, and vagina is disclosed. The composition comprises an aqueous solution of at least one polyol selected from the group consisting of xylitol, myoinositol and mannitol and at least one substance selected from the group consisting of glycerol and urea. The composition contains less than 0.01% inorganic salt and is free of any oil-in-water or wax-in-water emulsion. In particularly preferred embodiments, the composition comprises an aqueous solution containing 1.5-5% (w/v) xylitol and 0.9-2.0% (w/v) glycerol.

Claims (12)

1. A topical pharmaceutical or cosmetic composition for treatment of irritation of a mucous membrane of a nose, wherein said composition consists of:

1.4% (w/v) glycerol;

3.0% (w/v) xylitol;

0.01% (w/v) alanine; and,

the balance water.

2. A topical pharmaceutical or cosmetic composition for treatment of irritation of a mucous membrane of a nose, wherein said composition consists of:

1.4% (w/v) glycerol;

3.0% (w/v) xylitol;

0.01% (w/v) alanine;

an effective amount of a pharmaceutically acceptable preservative; and,

the balance water.

3. The topical pharmaceutical or cosmetic composition according to claim 2 , wherein said pharmaceutically acceptable preservative is selected from the group consisting of benzalkonium chloride; methyl paraben; cetrimonium bromide; and, sodium ethylene diamine tetraacetate.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2016
From: DIKSTEIN, SHABTAY
To: RESDEVCO RESEARCH AND DEVELOPMENT CO. LTD.
Reel/Frame 039971/0169 →
Priority Claims (1)
IL 168603 · May 16, 2005 · national
Continuity (2)
Continuation In Part 11914429
Related Publication 20170021023A1 · Jan 26, 2017